People · Operator
Named in public records as an officer, director or promoter · active 2025–2025 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Immuneering Corp | — | Pharmaceuticals | Series B | $82.2M | $111.0M | 2025 |
Thomas J. Schall at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Thomas J. Schall on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert J. Carpenter | 1 | 3 |
| Andrew J. Phillips | 1 | 2 |
| Benjamin J. Zeskind | 1 | 1 |
| Peter J. Feinberg | 1 | 1 |
| Joseph J. Kekst | 1 | 1 |
| Diana F. Hausman | 1 | 1 |
| Laurie B. Keating | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.